New Delhi: Human trials for India’s home developed coronavirus vaccine – COVAXIN, started on Monday, and researchers will get the first data set in at least three months, said Dr Randeep Guleria, Director, AIIMS Delhi.
According to reports, phase 1 of the three-phase trails started on a day when India reported 40,000 fresh cases, crossing the 11 lakh mark.
Around 1,125 healthy volunteers will be injected with inactivated Sars-CoV-2 so their body can produce Covid-fighting antibodies.
Phase-1 includes 375 volunteers in the age bracket of 18-55 with no co-morbidity; phase 2 will have 750 individuals in the age bracket of 12-65 and Phase 3 of the trial will done on a larger population.
Dr Guleria said that starting the trials with an indigenous vaccine is a promising step. And even if the vaccine is developed elsewhere, India will be mass producing it.
Taking about the trails, Dr Sanjay Rai, head of community medicine, who will be supervising the trials operations said, both men and women will be recruited, however, women volunteers can’t be pregnant.